<DOC>
	<DOC>NCT01440764</DOC>
	<brief_summary>The purpose of this protocol is to develop and test optimal delivery of aerosol furosemide, a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.</brief_summary>
	<brief_title>Aerosol Inhalation Treatment for Dyspnea</brief_title>
	<detailed_description>This is study of aerosol treatment in a laboratory model of dyspnea in healthy subjects. This study is the first in a series of studies that will include investigation of a second dose in the laboratory and investigation of the treatment effect in hospitalized patients with refractory dyspnea. The outcome of this first study will determine the details of protocol for the succeeding studies.</detailed_description>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>Healthy Unstable heart or circulation disease Stroke Seizure disorder Severe migraine headaches Liver or kidney disease Adrenal gland problem (Pheochromocytoma) Nerve problems that may affect your breathing sensation Brain cancer Drug or alcohol problem Systemic lupus erythematosis (SLE) High levels of depression, panic disorder, or other significant mental health problems Serious ongoing pain Pregnant Under 18 years old Not Fluent in English</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>dyspnea</keyword>
	<keyword>Laboratory model of dyspnea in healthy subjects</keyword>
</DOC>